Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4

Trial Profile

A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bidridistrogene xeboparvovec (Primary) ; Glucocorticoids
  • Indications Limb girdle muscular dystrophies
  • Focus Registrational; Therapeutic Use
  • Acronyms EMERGENE
  • Sponsors Sarepta Therapeutics
  • Most Recent Events

    • 15 Apr 2025 According to Sarepta Therapeutics media release, the company to submit a BLA to the U.S. FDA in the second half of 2025. Data expected in mid 2025.
    • 04 Mar 2025 Planned primary completion date changed from 31 Jan 2025 to 4 Mar 2025.
    • 18 Dec 2024 According to Sarepta Therapeutics media release, Data from EMERGENE are expected in the first half of 2025.Assuming a positive pre-Biologics License Application (BLA) meeting and supportive data from EMERGENE, Sarepta anticipates submitting a BLA to the U.S. Food and Drug Administration seeking accelerated approval for SRP-9003 in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top